Johnson & Johnson’s consumer unit is set to lay off 57 workers at its Greenfield plant in Pennsylvania, according to a report from Lancaster Online. The Worker Adjustment and Retraining Notification (WARN) notice shows that the layoffs will begin on February 28th.

According to Lancaster Online, the facility develops over-the-counter products that include Pepcid and Immodium.

The move comes as J&J is in the process of spinning off its consumer business, which will be named Kenvue. In February of last year, Lancaster Online reported that the Greenfield Plant which is being impacted by the layoffs, was set to be decommissioned by the fall of 2023.

J&J began a joint venture with Merck to develop consumer health products at the site. But in 2011 J&J purchased Merck’s stake in the joint venture between the two companies.

The layoffs are part of a growing trend in the medtech industry. Last month several companies announced the shedding of personnel.

In early February, Venus Concept, a manufacturer of medical aesthetic devices announced plans to cut its global workforce by about 18%, or 70 employees. 

About two weeks after Baxter announced it would shed nearly 5% of its workforce in a cost-savings measure. A day later, Vicarious Surgical said it would trim about 14% of its workforce.